IL13 and inflammatory bowel disease: In inflammatory bowel disease (IBD), a persistent state of inflammation will lead to leakage of the TJs of the patient's intestine, and butyrate enemas help to reduce intestinal inflammation in patients (57), while preserving TJ integrity and directly improving intestinal barrier function by inhibiting the release of TNF-α, IL-13, etc. (58–60).